US Patent 8426428 EGFR kinase knockdown via electrophilically enhanced inhibitors
Patent 8426428 was granted and assigned to Principia Biopharma Inc. on April, 2013 by the United States Patent and Trademark Office.
All edits
Edits on 12 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 29 Nov, 2023
Golden AI
Edits made to:
Article (+160 characters)
Article
Patent abstract
Provided herein are electrophilically enhanced kinase inhibitors of Formula I. Also provided herein are methods of making and utilizing the same.
Edits on 21 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Inventor Names
Richard Miller0
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08426428 EGFR kinase knockdown via electrophilically enhanced inhibitors US Patent 8426428 EGFR kinase knockdown via electrophilically enhanced inhibitors
Infobox
Patent Number
084264280
Patent Number
84264280
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
084264280
Date of Patent
April 23, 2013
0Patent Application Number
123294450
Date Filed
December 5, 2008
0Patent Primary Examiner
Edits on 16 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08426428 EGFR kinase knockdown via electrophilically enhanced inhibitors
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08426428
Date of patent
April 23, 2013
Patent application number
12329445
Date Filed
December 5, 2008
Patent primary examiner
Find more entities like US Patent 8426428 EGFR kinase knockdown via electrophilically enhanced inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
